Sight Sciences (Sight Sciences) Earnings per Share (Diluted) : $-1.12 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sight Sciences Earnings per Share (Diluted)?

Sight Sciences's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.33. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.12.

Sight Sciences's EPS (Basic) for the three months ended in Mar. 2024 was $-0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.12.

Sight Sciences's EPS without NRI for the three months ended in Mar. 2024 was $-0.33. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.12.

During the past 3 years, the average EPS without NRIGrowth Rate was -4.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -25.70% per year.

During the past 6 years, Sight Sciences's highest 3-Year average EPS without NRI Growth Rate was -4.80% per year. The lowest was -74.50% per year. And the median was -30.90% per year.

Sight Sciences Earnings per Share (Diluted) Historical Data

The historical data trend for Sight Sciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sight Sciences Earnings per Share (Diluted) Chart

Sight Sciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-0.80

-0.99

-2.36

-1.80

-1.14

Sight Sciences Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Earnings per Share (Diluted)	Get a 7-Day Free Trial														-0.35	-0.30	-0.27	-0.22	-0.33

Competitive Comparison of Sight Sciences's Earnings per Share (Diluted)

For the Medical Devices subindustry, Sight Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sight Sciences's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sight Sciences's PE Ratio falls into.

Sight Sciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Sight Sciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-55.547	-	0)	/	48.629
	=	-1.14

Sight Sciences's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-16.266	-	0)	/	49.486
	=	-0.33

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.12

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Sight Sciences (NAS:SGHT) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sight Sciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Sight Sciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sight Sciences (Sight Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sight Sciences Inc (NAS:SGHT) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.sightsciences.com

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Executives

Jeremy B. Hayden	officer: Chief Legal Officer	2 MUSICK, 2 MUSICK, IRVINE CA 92618
Sam Boong Park	officer: Chief Operating Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Paul Badawi	director, 10 percent owner, officer: President and CEO	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
David Badawi	director, officer: Chief Technology Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
D1 Capital Partners L.p.	10 percent owner	9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Staffan Encrantz	director	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Matthew Link	officer: Chief Commercial Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Catherine Mazzacco	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Alison Bauerlein	officer: See remarks	326 BOLLAY DRIVE, GOLETA CA 93117
James Rodberg	officer: See Remarks	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025
Tamara Fountain	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Brenda Jane Larsen-becker	director	C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025
Jesse Selnick	officer: Chief Financial Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Daniel S. Sundheim	10 percent owner	C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Erica J. Rogers	director	C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089